Rheumatoid Arthritis
Medications: Most people who have rheumatoid arthritis take medications. Some medications are used only for pain relief; others are used to reduce inflammation. Still others, often called disease-modifying antirheumatic drugs (DMARDs), are used to try to slow the course of the disease. The person's general condition, the current and predicted severity of the illness, the length of time he or she will take the drug, and the drug's effectiveness and potential side effects are important considerations in prescribing drugs for rheumatoid arthritis. The shows currently used rheumatoid arthritis medications, along with their uses and effects, side effects, and monitoring requirements.
Biologic response modifiers are new drugs used for the treatment of rheumatoid arthritis. They can help reduce inflammation and structural damage to the joints by blocking the action of cytokines, proteins of the body's immune system that trigger inflammation during normal immune responses. Three of these drugs, etanercept (Enbrel*), infliximab (Remicade), and adalimumab (Humira), reduce inflammation by blocking the reaction of TNF-? molecules. Another drug, called anakinra (Kineret), works by blocking a protein called interleukin 1 (IL-1) that is seen in excess in patients with rheumatoid arthritis.
For many years, doctors initially prescribed aspirin or other pain-relieving drugs for rheumatoid arthritis, as well as rest and physical therapy. They usually prescribed more powerful drugs later only if the disease worsened.
Today, however, many doctors have changed their approach, especially for patients with severe, rapidly progressing rheumatoid arthritis. Studies show that early treatment with more powerful drugs, and the use of drug combinations instead of one medication alone, may be more effective in reducing or preventing joint damage. Once the disease improves or is in remission, the doctor may gradually reduce the dosage or prescribe a milder medication.
* Brand names included in this booklet are provided as examples only, and their inclusion does not mean that these products are endorsed by the National Institutes of Health or any other Government agency. Also, if a particular brand name is not mentioned, this does not mean or imply that the product is unsatisfactory.
Surgery: Several types of surgery are available to patients with severe joint damage. The primary purpose of these procedures is to reduce pain, improve the affected joint\'s function, and improve the patient\'s ability to perform daily activities. Surgery is not for everyone, however, and the decision should be made only after careful consideration by patient and doctor. Together they should discuss the patient's overall health, the condition of the joint or tendon that will be operated on, and the reason for, as well as the risks and benefits of, the surgical procedure. Cost may be another factor. Commonly performed surgical procedures include joint replacement, tendon reconstruction, and synovectomy.
Joint replacement: This is the most frequently performed surgery for rheumatoid arthritis, and it is done primarily to relieve pain and improve or preserve joint function. Artificial joints are not always permanent and may eventually have to be replaced. This may be an important consideration for young people.
Tendon reconstruction: Rheumatoid arthritis can damage and even rupture tendons, the tissues that attach muscle to bone. This surgery, which is used most frequently on the hands, reconstructs the damaged tendon by attaching an intact tendon to it. This procedure can help to restore hand function, especially if the tendon is completely ruptured.
Synovectomy: In this surgery, the doctor actually removes the inflamed synovial tissue. Synovectomy by itself is seldom performed now because not all of the tissue can be removed, and it eventually grows back. Synovectomy is done as part of reconstructive surgery, especially tendon reconstruction.
Routine Monitoring and Ongoing Care: Regular medical care is important to monitor the course of the disease, determine the effectiveness and any negative effects of medications, and change therapies as needed. Monitoring typically includes regular visits to the doctor. It also may include blood, urine, and other laboratory tests and x rays.
People with rheumatoid arthritis may want to discuss preventing osteoporosis with their doctors as part of their long-term, ongoing care. Osteoporosis is a condition in which bones become weakened and fragile. Having rheumatoid arthritis increases the risk of developing osteoporosis for both men and women, particularly if a person takes corticosteroids. Such patients may want to discuss with their doctors the potential benefits of calcium and vitamin D supplements, hormone therapy, or other treatments for osteoporosis.
Alternative and Complementary Therapies: Special diets, vitamin supplements, and other alternative approaches have been suggested for treating rheumatoid arthritis. Although many of these approaches may not be harmful in and of themselves, controlled scientific studies either have not been conducted on them or have found no definite benefit to these therapies. Some alternative or complementary approaches may help the patient cope or reduce some of the stress associated with living with a chronic illness. As with any therapy, patients should discuss the benefits and drawbacks with their doctors before beginning an alternative or new type of therapy. If the doctor feels the approach has value and will not be harmful, it can be incorporated into a patient's treatment plan. However, it is important not to neglect regular health care. The Arthritis Foundation publishes material on alternative therapies as well as established therapies, and patients may want to contact this organization for information.
| Medications | Uses/Effects | Side Effects | Monitoring |
|---|---|---|---|
| Analgesics and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | Analgesics relieve pain; NSAIDs are a large class of medications useful against pain and inflammation. A number of NSAIDs are available over the counter. More than a dozen others?including a subclass called COX-2 inhibitors?are available only with a prescription. | NSAIDs can cause stomach irritation or, less often, can affect kidney function. The longer a person uses NSAIDs, the more likely he or she is to have side effects, ranging from mild to serious. Many other drugs cannot be taken when a patient is being treated with NSAIDs because they alter the way the body uses or eliminates these other drugs. NSAIDs sometimes are associated with serious gastrointestinal problems, including ulcers, bleeding, and perforation of the stomach or intestine. People over age 65 and those with any history of ulcers or gastrointestinal bleeding should use NSAIDs with caution. | Check with your health care provider or pharmacist before you take NSAIDs. Before taking traditional NSAIDs, let your provider know if you drink alcohol or use blood thinners or if you have any of the following: sensitivity or allergy to aspirin or similar drugs, kidney or liver disease, heart disease, high blood pressure, asthma, or peptic ulcers. |
| Acetaminophen | Nonprescription medications used to relieve pain. Examples are aspirin-free Anacin*, Excedrin caplets, Panadol, Tylenol, and Tylenol Arthritis. | Usually no side effects when taken as directed. | Not to be taken with alcohol or with other products containing acetaminophen. Not to be used for more than 10 days unless directed by a physician. |
| Aspirin Buffered Plain |
Aspirin is used to reduce pain, swelling, and inflammation, allowing patients to move more easily and carry out normal activities. It is generally part of early and ongoing therapy. | Upset stomach; tendency to bruise easily; ulcers, pain, or discomfort; diarrhea; headache; heartburn or indigestion; nausea or vomiting. | Doctor monitoring is needed. |
| * NOTE: Brand names included in this booklet are provided as examples only, and their inclusion does not mean that these products are endorsed by the National Institutes of Health or any other Government agency. Also, if a particular brand name is not mentioned, this does not mean or imply that the product is unsatisfactory. | |||
| Traditional NSAIDs Ibuprofen Ketoprofen Naproxen |
NSAIDs help relieve pain within hours of admin-istration in dosages available over-the-counter (available for all three medications). They relieve pain and inflammation in dosages available in prescription form (ibu-profen and ketoprofen). It may take several days to reduce inflammation. | For all traditional NSAIDs: Abdominal or stomach cramps, pain, or discomfort; diarrhea; dizziness; drowsiness or light-headedness; headache; heartburn or indigestion; peptic ulcers; nausea or vomiting; possible kidney and liver damage (rare). | For all traditional NSAIDs: Before taking these drugs, let your doctor know if you drink alcohol or use blood thinners or if you have or have had any of the following: sensitivity or allergy to aspirin or similar drugs, kidney or liver disease, heart disease, high blood pressure, asthma, or peptic ulcers. |
| Corticosteroids | These are steroids given by mouth or injection. They are used to relieve inflammation and reduce swelling, redness, itching, and allergic reactions. | Increased appetite, indigestion, nervousness, or restlessness. | For all corticosteroids, let your doctor know if you have one of the following: fungal infection, history of tuberculosis, underactive thyroid, herpes simplex of the eye, high blood pressure, osteoporosis, or stomach ulcer. |
| Methylprednisolone Prednisone |
These steroids are available in pill form or as an injection into a joint. Improvements are seen in several hours up to 24 hours after administration. There is potential for serious side effects, especially at high doses. They are used for severe flares and when the disease does not respond to NSAIDs and DMARDs. | Osteoporosis, mood changes, fragile skin, easy bruising, fluid retention, weight gain, muscle weakness, onset or worsening of diabetes, cataracts, increased risk of infection, hyper-tension (high blood pressure). | Doctor monitoring for continued effectiveness of medication and for side effects is needed. |
| Disease-modifying antirheumatic drugs (DMARDs) | These are common arthritis medications. They relieve painful, swollen joints and slow joint damage, and several DMARDs may be used over the disease course. They take a few weeks or months to have an effect, and may produce significant improvements for many patients. Exactly how they work is still unknown. | Side effects vary with each medicine. DMARDs may increase risk of infection, hair loss, and kidney or liver damage. | Doctor monitoring allows the risk of toxicities to be weighed against the potential benefits of individual medications. |
| Azathioprine | This drug was first used in higher doses in cancer chemotherapy and organ transplantation. It is used in patients who have not responded to other drugs, and in combination therapy. | Cough or hoarseness, fever or chills, loss of appetite, lower back or side pain, nausea or vomiting, painful or difficult urination, unusual tiredness or weakness. | Before taking this drug, tell your doctor if you use allopurinol or have kidney or liver disease. This drug can reduce your ability to fight infection, so call your doctor immediately if you develop chills, fever, or a cough. Regular blood and liver function tests are needed. |
| Cyclosporine | This medication was first used in organ transplantation to prevent rejection. It is used in patients who have not responded to other drugs. | Bleeding, tender, or enlarged gums; high blood pressure; increase in hair growth; kidney problems; trembling and shaking of hands. | Before taking this drug, tell your doctor if you have one of the following: sensitivity to castor oil (if receiving the drug by injection), liver or kidney disease, active infection, or high blood pressure. Using this drug may make you more susceptible to infection and certain cancers. Do not take live vaccines while on this drug. |
| Hydroxychloroquine | It may take several months to notice the benefits of this drug, which include reducing the signs and symptoms of rheumatoid arthritis. | Diarrhea, eye problems (rare), headache, loss of appetite, nausea or vomiting, stomach cramps or pain. | Doctor monitoring is important, particularly if you have an allergy to any antimalarial drug or a retinal abnormality. |
| Gold sodium thiomalate | This was one of the first DMARDs used to treat rheumatoid arthritis. | Redness or soreness of tongue; swelling or bleeding gums; skin rash or itching; ulcers or sores on lips, mouth, or throat; irritation on tongue. Joint pain may occur for one or two days after injection. | Before taking this drug, tell your doctor if you have any of the following: lupus, skin rash, kidney disease, or colitis. Periodic urine and blood tests are needed to check for side effects. |
| Leflunomide | This drug reduces signs and symptoms and slows structural damage to joints caused by arthritis. | Bloody or cloudy urine; congestion in chest; cough; diarrhea; difficult, burning, or painful urination or breathing; fever; hair loss; headache; heartburn; loss of appetite; nausea and/or vomiting; skin rash; stomach pain; sneezing; and sore throat. | Before taking this medication, let your doctor know if you have one of the following: active infection, liver disease, known immune deficiency, renal insufficiency, or underlying malignancy. You will need regular blood tests, including liver function tests. Leflunomide must not be taken during pregnancy because it may cause birth defects in humans. |
| Methotrexate | This drug can be taken by mouth or by injection and results in rapid improvement (it usually takes 3-6 weeks to begin working). It appears to be very effective, especially in combination with infliximab or etanercept. In general, it produces more favorable long-term responses compared with other DMARDs such as sulfasalazine, gold sodium thiomalate, and hydroxychloroquine. | Abdominal discomfort, chest pain, chills, nausea, mouth sores, painful urination, sore throat, unusual tiredness or weakness. | Doctor monitoring is important, particularly if you have an abnormal blood count, liver or lung disease, alcoholism, immune-system deficiency, or active infection. Methotrexate must not be taken during pregnancy because it may cause birth defects in humans. |
| Sulfasalazine | This drug works to reduce the signs and symptoms of rheumatoid arthritis by suppressing the immune system. | Abdominal pain, aching joints, diarrhea, headache, sensitivity to sunlight, loss of appetite, nausea or vomiting, skin rash. | Doctor monitoring is important, particularly if you are allergic to sulfa drugs or aspirin, or if you have a kidney, liver, or blood disease. |
| Biologic Response Modifiers | These drugs selectively block parts of the immune system called cytokines. Cytokines play a role in inflammation. Long-term efficacy and safety are uncertain. | Increased risk of infection, especially tuberculosis. Increased risk of pneumonia, and listeriosis (a foodborne illness caused by the bacterium Listeria monocytogenes). | It is important to avoid eating undercooked foods (including unpasteurized cheeses, cold cuts, and hot dogs) because undercooked food can cause listeriosis for patients taking biologic response modifiers. |
| Tumor Necrosis Factor Inhibitors Etanercept Infliximab Adalimumab |
These medications are highly effective for treating patients with an inadequate response to DMARDs. They may be prescribed in combination with some DMARDs, particularly methotrexate. Etanercept requires subcutaneous (beneath the skin) injections two times per week. Infliximab is taken intravenously (IV) during a 2-hour procedure. It is administered with methotrexate. Adalimumab requires injections every 2 weeks. Long-term efficacy and safety are uncertain. | Etanercept: Pain or burning in throat; redness, itching, pain, and/or swelling at injection site; runny or stuffy nose. Infliximab: Abdominal pain, cough, dizziness, fainting, headache, muscle pain, runny nose, shortness of breath, sore throat, vomiting, wheezing. Adalimumab: Redness, rash, swelling, itching, bruising, sinus infection, headache, nausea. |
Long-term efficacy and safety are uncertain. Doctor monitoring is important, particularly if you have an active infection, exposure to tuberculosis, or a central nervous system disorder. Evaluation for tuberculosis is necessary before treatment begins. |
| Interleukin1 Inhibitor Anakinra |
This medication requires daily injections. Long-term efficacy and safety are uncertain. | Redness, swelling, bruising, or pain at the site of injection; head-ache; upset stomach; diarrhea; runny nose; and stomach pain. | Doctor monitoring is required. |
Current Research
Over the last several decades, research has greatly increased our understanding of the immune system, genetics, and biology. This research is now showing results in several areas important to rheumatoid arthritis. Scientists are thinking about rheumatoid arthritis in exciting ways that were not possible even 10 years ago.
The National Institutes of Health (NIH) funds a wide variety of medical research at its headquarters in Bethesda, Maryland, and at universities and medical centers across the United States. One of the NIH institutes, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is a major supporter of research and research training in rheumatoid arthritis through grants to individual scientists, Specialized Centers of Research, Multidisciplinary Clinical Research Centers, and Multipurpose Arthritis and Musculoskeletal Diseases Centers.
Following are examples of current research directions in rheumatoid arthritis supported by the Federal Government through the NIAMS and other parts of the NIH.
Scientists are looking at the immune systems of people with rheumatoid arthritis and in some animal models of the disease to understand why and how the disease develops. For example, small studies are looking at the role of T cells, which play an important role in immunity and in the progression of rheumatoid arthritis. Findings from these studies may lead to precise, targeted therapies that could stop the inflammatory process in its earliest stages. They may even lead to a vaccine that could prevent rheumatoid arthritis.
Researchers are studying genetic factors that predispose some people to developing rheumatoid arthritis, as well as factors connected with disease severity. For example, by studying genetically engineered mice, scientists supported by the NIH discovered that immune cells called mast cells play a key role in the development of rheumatoid arthritis. Findings from these studies should increase our understanding of the disease and will help develop new therapies, as well as guide treatment decisions.
In a major effort aimed at identifying genes involved in rheumatoid arthritis, the NIH and the Arthritis Foundation have joined together to support the North American Rheumatoid Arthritis Consortium. This group of 10 research centers around the United States is collecting medical information and genetic material from 1,000 families in which two or more siblings have rheumatoid arthritis. It serves as a national resource for genetic studies of this disease.
To help identify the multiple factors that predict disease course and outcomes in rheumatoid arthritis in African Americans, the NIH is supporting the Consortium for the Longitudinal Evaluations of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry at the University of Alabama at Birmingham. This registry aims to collect clinical and x-ray data and DNA to help scientists analyze genetic and nongenetic factors that predict disease course and outcomes of rheumatoid arthritis.
Scientists are also unearthing the genetic basis of rheumatoid arthritis by studying rats with a condition that resembles rheumatoid arthritis in humans. NIAMS researchers have identified several genetic regions that affect arthritis susceptibility and severity in these animal models of the disease. These genetic regions are important because they can assist scientists in predicting the symptoms and severity of rheumatoid arthritis. Replacing malfunctioning genes with healthy genes (gene transfer) is being tested in mice, and it may eventually be used in humans to treat rheumatoid arthritis.
Researchers are also uncovering the complex relationships between the hormonal, nervous, and immune systems in rheumatoid arthritis. For example, they are exploring whether and how the normal changes in the levels of naturally produced steroid hormones (such as estrogen and testosterone) during a person\'s lifetime may be related to the development, improvement, or flares of the disease. Scientists also are researching how these systems interact with environmental and genetic factors. The results of this research may suggest new treatment strategies.
Scientists are exploring why so many more women than men develop rheumatoid arthritis. In hopes of finding clues, they are studying female and male hormones and other differences between women and men.
Scientists are examining why rheumatoid arthritis often improves during pregnancy. Results of one study suggest that the explanation may be related to differences in certain special proteins that pass between a mother and her unborn child. These proteins help the immune system distinguish between the body\'s own cells and foreign cells. Such differences, the scientists speculate, may change the activity of the mother\'s immune system during pregnancy.
A growing body of evidence indicates that infectious agents, such as viruses and bacteria, may trigger rheumatoid arthritis in people who have an inherited predisposition to the disease. Scientists are trying to discover which infectious agents may be responsible and how they trigger arthritis.
Researchers are searching for new drugs or combinations of drugs that can reduce inflammation and slow or stop the progression of rheumatoid arthritis with few side effects. Already, the new biologic response modifiers infliximab and etanercept are proving to be extremely effective for some people. Studies show that these treatments are more effective at slowing joint damage than methotrexate alone. Combination treatment with etanercept and methotrexate or infliximab and methotrexate has been found even more effective than either of the new treatments alone. (Methotrexate was used for comparison because it is a commonly prescribed ?front-line? treatment.) The U.S. Food and Drug Administration recently approved adalimumab (Humira) for slowing the progression of structural damage in adults with moderate to severe rheumatoid arthritis who have not responded well to one or more disease modifying antirheumatic drugs.
Investigators have also shown that treatment of rheumatoid arthritis with minocycline, a drug in the tetracycline family, has a modest benefit. Other studies have shown that the omega-3 fatty acids in certain fish or plant seed oils also may reduce rheumatoid arthritis inflammation. However, many people are not able to tolerate the large amounts of oil necessary for any benefit.
Scientists are examining many issues related to quality of life for people with rheumatoid arthritis and the quality, cost, and effectiveness of the health care services they receive. Some new techniques for managing symptoms under investigation include tai chi (a form of movement-based meditation), and cognitive-behavioral therapy (a technique that teaches you to anticipate and prepare yourself for the situations and bodily sensations that may trigger painful symptoms). Scientists have found that even a small improvement in a patient\'s sense of physical and mental well-being can have an impact on his or her quality of life and use of health care services.
Hope for the Future
Scientists are making rapid progress in understanding the complexities of rheumatoid arthritis: how and why it develops, why some people get it and others do not, why some people get it more severely than others. Results from research are having an impact today, enabling people with rheumatoid arthritis to remain active in life, family, and work far longer than was possible 20 years ago. There is also hope for tomorrow, as researchers begin to apply new technologies such as stem cell transplantation and novel imaging techniques. (Stem cells have the capacity to differentiate into specific cell types, which gives them the potential to change damaged tissue in which they are placed.) These and other advances will lead to an improved quality of life for people with rheumatoid arthritis.
For More Information
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health
1 AMS Circle
Bethesda, MD 20892-3675
(301) 495-4484 or
(877) 22-NIAMS (226-4267) (free of charge)
Fax: (301) 718-6366
TTY: (301) 565-2966
E-mail: www.niamsinfo.nih.gov
World Wide Web address: http://www.niams.nih.gov
The National Institute of Arthritis and Musculoskeletal and Skin Diseases provides information about various forms of arthritis and rheumatic diseases. It distributes patient and professional education materials and also refers people to other sources of information.
The National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 31, Room 7A50
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520
(301) 496-5717
Fax: (301) 402-0120
The National Institute of Allergy and Infectious Diseases conducts and supports research that strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten hundreds of millions of people worldwide. The Institute\'s mission is driven by a strong commitment to basic research and the understanding that the fields of immunology, microbiology, and infectious disease are related and complementary.
National Center for Complementary and Alternative Medicine
NCCAM Clearinghouse
P.O. Box 7923
Gaithersburg, MD 20898-7923
(301) 519-3153 or
(888) 644-6226 (free of charge)
Fax: (866) 464-3616
TTY: (866) 464-3615
The National Center for Complementary and Alternative Medicine is dedicated to exploring complementary and alternative healing practices in the context of rigorous science, training complementary and alternative medicine researchers, and disseminating authoritative information to the public and professionals.
American Academy of Orthopaedic Surgeons
P.O. Box 2058
Des Plains, IL 60017
(800) 824-BONE (2263) (free of charge)
www.aaos.org
The Academy provides education and practice management services for orthopaedic surgeons and allied health professionals. It also serves as an advocate for improved patient care and informs the public about the science of orthopaedics. The orthopaedist\'s scope of practice includes disorders of the body\'s bones, joints, ligaments, muscles, and tendons. For a single copy of an AAOS brochure, send a self-addressed, stamped envelope to the address above or visit the AAOS Web site.
American College of Rheumatology
1800 Century Place, Suite 250
Atlanta, GA 30345
(404) 633-3777
Fax: (404) 633-1870
www.rheumatology.org
The College provides referrals to rheumatologists and physical and occupational therapists who have experience working with people who have rheumatoid arthritis. The organization also provides educational materials and guidelines.
Arthritis Foundation
P.O. Box 7669
Atlanta, GA 30357-0669
(404) 872-7100 or (800) 568-4045 (free of charge) or your local chapter, listed in the telephone directory
www.arthritis.org
The Arthritis Foundation is the major voluntary organization devoted to supporting arthritis research and providing educational and other services to individuals with arthritis. The Foundation publishes a free pamphlet on rheumatoid arthritis and a magazine for members on all types of arthritis. It also provides up-to-date information on research and treatment, nutrition, alternative therapies, and self-management strategies. Chapters nationwide offer exercise programs, classes, support groups, physician referral services, and free literature.
Acknowledgments
The NIAMS gratefully acknowledges the assistance of the following people in the preparation and review of this and earlier versions of this publication: John H. Klippel, M.D., Arthritis Foundation, Washington, DC; Amye L. Leong, Paris, France; Michael D. Lockshin, M.D., Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, New York; Kate Lorig, R.N., Dr.P.H., Stanford University, Stanford, California; J. Lee Nelson, M.D., Fred Hutchinson Cancer Research Center, Seattle, Washington; Paul G. Rochmis, M.D., Fairfax, Virginia; Ronald L. Wilder, M.D., Ph.D., MedImmune, Inc., Gaithersburg, Maryland; Stanley R. Pillemer, M.D, NIH; and Reva Lawrence, M.P.H., Paul H. Plotz, M.D., and Susana Serrate-Sztein, M.D., NIAMS, NIH. Special thanks also go to Cheryl Yarboro, R.N., B.S.P.A., NIAMS, NIH, and to the patients who reviewed this publication and provided valuable input.
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services\' National Institutes of Health (NIH), is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases. The National Institute of Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse is a public service sponsored by the NIAMS that provides health information and information sources. Additional information can be found on the NIAMS Web site at www.niams.nih.gov.
NIH Publication No. 04-4179